{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:47:39Z","timestamp":1783691259745,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-023-00841-3","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T17:01:52Z","timestamp":1702486912000},"page":"277-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early transition to avacopan from glucocorticoids applied during induction therapy for microscopic polyangiitis with rapidly progressive glomerulonephritis"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4183-6762","authenticated-orcid":false,"given":"Hiromasa","family":"Miyake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Yamaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"841_CR1","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","volume":"76","author":"JA Tan","year":"2017","unstructured":"Tan JA, Dehghan N, Chen W, et al. Mortality in ANCA-associated vasculitis; a meta-analysis of observational studies. Ann Rheum Dis. 2017;76:1566\u201374.","journal-title":"Ann Rheum Dis"},{"key":"841_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599\u2013609.","journal-title":"N Engl J Med"},{"key":"841_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2021.11.036","volume":"7","author":"JR van Leeuwen","year":"2021","unstructured":"van Leeuwen JR, Bredewold OW, van Dam LS, et al. Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int Rep. 2021;7:624\u20138.","journal-title":"Kidney Int Rep"},{"key":"841_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","volume":"81","author":"R Suppiah","year":"2022","unstructured":"Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81:321\u20136.","journal-title":"Ann Rheum Dis"},{"key":"841_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","author":"B Hellmich","year":"2023","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR\u00a0recommendations\u00a0for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023. https:\/\/doi.org\/10.1136\/ard-2022-223764.","journal-title":"Ann Rheum Dis"},{"key":"841_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","volume":"8","author":"FB Cortazar","year":"2023","unstructured":"Cortazar FB, Niles JL, Jayne DRW, et al. Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of Avacopan. Kidney Int Rep. 2023;8:860\u201370.","journal-title":"Kidney Int Rep"},{"key":"841_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3109\/14397595.2016.1140274","volume":"26","author":"KE Sada","year":"2016","unstructured":"Sada KE, Harigai M, Amano K, et al. Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Mod Rheumatol. 2016;26:730\u20137.","journal-title":"Mod Rheumatol"},{"key":"841_CR8","doi-asserted-by":"publisher","first-page":"kead087","DOI":"10.3109\/14397595.2016.1140274","volume":"21","author":"D Turgeon","year":"2023","unstructured":"Turgeon D, Bakowsky V, Baldwin C, et al. CanVasc\u00a0consensus\u00a0recommendations\u00a0for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum. Rheumatology (Oxford). 2023;21:kead087. https:\/\/doi.org\/10.3109\/14397595.2016.1140274.","journal-title":"Rheumatology (Oxford)"},{"key":"841_CR9","unstructured":"Harigai M, Narita I, Suda T, et al. 2023 Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis. SHINDAN TO CHIRYO SHA Inc; 2023"},{"key":"841_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.06460622","volume":"18","author":"M Casal Moura","year":"2023","unstructured":"Casal Moura M, Specks U, Tehranian S, et al. Maintenance of remission and risk of relapse in myeloperoxidase-positive ANCA-Associated Vasculitis with Kidney Involvement. Clin J Am Soc Nephrol. 2023;18:47\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"key":"841_CR11","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/rheumatology\/keac623","volume":"62","author":"B Chevet","year":"2023","unstructured":"Chevet B, Cornec D, Casal Moura M, et al. Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice. Rheumatology (Oxford). 2023;62:1787\u2013803.","journal-title":"Rheumatology (Oxford)"},{"key":"841_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrneph.2017.37","volume":"13","author":"M Chen","year":"2017","unstructured":"Chen M, Jayne DRW, Zhao MH. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol. 2017;13:359\u201367.","journal-title":"Nat Rev Nephrol"},{"key":"841_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888816","volume":"13","author":"V Tesar","year":"2022","unstructured":"Tesar V, Hruskova Z. Complement inhibition in ANCA-associated vasculitis. Front Immunol. 2022;13: 888816.","journal-title":"Front Immunol"},{"key":"841_CR14","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1093\/rheumatology\/kead191","volume":"62","author":"Y Abe","year":"2023","unstructured":"Abe Y, Minowa K, Kogami M, et al. Avacopan is possibly associated\u00a0with the\u00a0improvement\u00a0of ANCA-associated\u00a0vasculitis activity without decreasing ANCA titres: a four-case series. Rheumatology (Oxford). 2023;62:e317.","journal-title":"Rheumatology (Oxford)"},{"key":"841_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/mr\/roac037","volume":"33","author":"M Harigai","year":"2023","unstructured":"Harigai M, Kaname S, Tamura N, et al. Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: a subanalysis of a randomized Phase 3 study. Mod Rheumatol. 2023;33:338\u201345.","journal-title":"Mod Rheumatol"},{"key":"841_CR16","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256\u201364.","journal-title":"Nat Biotechnol"},{"key":"841_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/mrcr\/rxad019","volume":"7","author":"H Kataoka","year":"2023","unstructured":"Kataoka H, Tomita T, Nakanowatari M, et al. Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol Case Rep. 2023;7:444\u20137.","journal-title":"Mod Rheumatol Case Rep"},{"key":"841_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-236236","volume":"13","author":"D Ennis","year":"2020","unstructured":"Ennis D, Yeung RS, Pagnoux C. Long-term use and remission of granulomatosis with polyangiitis with the oral C5a receptor inhibitor avacopan. BMJ Case Rep. 2020;13: e236236.","journal-title":"BMJ Case Rep"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00841-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-023-00841-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-023-00841-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T10:14:16Z","timestamp":1722507256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-023-00841-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1007\/s13730-023-00841-3","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"18 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}}]}}